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Abstract 26 
Background: Daptomycin dose is adjusted to body weight and renal function and is usually 27 
not guided by therapeutic drug monitoring (TDM). Daptomycin plasma concentration 28 
measurement was established at our institution in January 2009 and is now increasingly being 29 
used. The aim of this study was to describe and characterize variability in daptomycin exposure 30 
during routine clinical therapy. 31 
Methods: We collected daptomycin plasma concentrations that were measured at our 32 
institution during the period  January 2009-July 2012. Additional clinical and demographic data  33 
and their association with daptomycin exposure was tested by a multilevel linear regression 34 
analysis. 35 
Results: A total of 332 daptomycin plasma concentrations were determined in 86 patients. 66% 36 
(n=218) of all determinations were trough concentrations (Cmin) and 34% (n=114) were peak 37 
concentrations (Cmax). Cmin ranged 2-68mg/L (median 16.7mg/L) and Cmax 20-236mg/L 38 
(median 66.2mg/L). A significant positive association of total dose, albumin, creatinine, and a 39 
significant negative association of dose interval and intermittent haemodialysis with Cmin was 40 
found in the regression analysis. Total dose and Intensive Care Unit (ICU)_-stay was 41 
significantly associated with Cmax (P<0.05). However, only 28% (P<0.005) of Cmin 42 
variability and 8% (P=0.08) of Cmax variability was explained by the factors included in the 43 
analysis. 44 
Conclusion: Daptomycin plasma concentrations are often unpredictable as shown by highly 45 
variable drug exposure that is only partially explained by dose administered and underlying 46 
renal function. 47 
 48 
 49 
50 
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 51 
 52 
Introduction 53 
Therapeutic drug monitoring (TDM) is established for a number of anti-infective agents that 54 
are used in clinical care. Therapeutic plasma concentrations are defined based on clinical 55 
studies comparing plasma drug exposure to clinical efficacy and toxicity[1]. Although a 56 
toxicity threshold has been proposed for daptomycin induced CPK-elevation, no clinical trials 57 
exist that define optimal effective daptomycin plasma concentrations in different types of 58 
infection. Daptomycin (Cubicin®, Novartis, Basel, Switzerland) is a lipopeptide antibiotic 59 
active against Gram-positive organisms including methicillin-resistant Staphylococcus aureus 60 
or vancomycin-resistant Enterococci ssp[2]. The actual labelled dose is 4mg/kg once daily for 61 
the treatment of complicated skin and soft tissue infections (cSSTI) and 6mg/kg for blood 62 
stream infections, including those with right-sided endocarditis caused by methicillin-resistant 63 
S.aureus and methicillin-susceptible strains[3]. Data that correlate daptomycin concentration 64 
and antimicrobial killing are derived from in vitro or animal studies where a concentration-65 
dependent effect of daptomycin has been demonstrated, with area under the concentration 66 
curve (AUC)/minimal inhibitory concentration (MIC) ratio and peak concentrations (Cmax) 67 
/MIC ratio being the main determinants of bactericidal effect[4, 5].  68 
Based on these findings, higher doses are recommended in severe and difficult to treat Gram- 69 
positive infections, such as bacteraemia, infective endocarditis and osteomyelitis[6], and in 70 
critically ill patients[7]. Daptomycin use and efficacy in different types of infection has mainly 71 
been investigated in retrospective studies[8, 9] where the focus was to investigate dosing 72 
regimen and outcome; daptomycin plasma concentrations were not determined in these studies. 73 
As daptomycin is mainly eliminated by the kidneys, prolongation of dosing interval from 24 74 
hours (q24h) to 48 hours (q48h) is indicated in patients with a reduced glomerular filtration rate 75 
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(GFR) of <30mL/min with or without intermittent haemodialysis. Independent of the degree of 76 
renal impairment und type of renal replacement therapy used, high variability of daptomycin 77 
plasma concentrations can occur[10-12]. This is particularly the case in critically ill patients 78 
with Gram-positive sepsis, higher volume of distribution and increased daptomycin clearance 79 
has been observed with highly variable drug exposure leading to very low drug concentration in 80 
certain patients [7, 13, 14]. Therefore, TDM in these special populations might be warranted to 81 
optimize the dosing regimen and prevent either underdosing or excessive drug exposure 82 
associated with creatinine phosphokinase (CPK) elevation [15].  83 
Daptomycin plasma concentration measurement at our institution was established in January 84 
2009 and has now increasingly been used especially in the intensive care setting. The aim of 85 
this study was to investigate treatment indications in which daptomycin therapeutic drug 86 
monitoring was performed, to describe variability of daptomycin plasma concentrations and to 87 
determine the main factors associated with excessive or low drug exposure.   88 
 89 
Material and Methods 90 
In this retrospective chart review, we included all patients treated with daptomycin at the 91 
University Hospital in Zurich in the period January 2009 - July 2012 with at least one 92 
determination of daptomycin plasma concentration. The study was approved by the local Ethics 93 
Committee, Zurich, Switzerland. Samples were analysed by LC-MS/MS at the Institute of 94 
Clinical Chemistry as previously described[11]. The lower limit of quantification of the method 95 
was 0.03 mg/L, the precision 3.1% and the accuracy 101%. 96 
We collected all available daptomycin plasma concentrations determined, clinical and 97 
demographic data, the corresponding dosage, dosing interval and renal function or type of renal 98 
replacement therapy at the time of measurement. Cmin was usually determined just before the 99 
next infusion and Cmax immediately after the end of infusion. Cubicin® was infused over 100 
30minutes in all but one patient which received the infusion as a bolus over 2 minutes. In order 101 
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to characterize daptomycin dose as a function of body weight, total single administered dose 102 
recorded in the patient records was divided by body weight (kilogram).  103 
Patients were divided in 4 Groups according to renal function and type of renal replacement 104 
applied: Group 1, creatinine clearance (CrCl) >30mL/min; Group 2, CrCl ≤30mL/min and no 105 
renal replacement therapy; Group 3, end stage renal disease with intermittent hemodialysis 106 
(IHD); Group 4, renal failure requiring continuous renal replacement therapy (CRRT). CRRT 107 
was performed either with Multifiltrate (Fresenius Medical Care, Homburg, Germany) using 108 
the capillary hemofilter AV 1000s (polysulfone, surface area 1.8 m
2
) or with Prismaflex ST150 109 
(Gambro AB, Lund, Sweden) using the capillary hemofilter AN69 ST (acrylonitril-sodium-110 
methylsulfonate, surface area 1.5m
2
). In 72 of 86 patients, CrCl was estimated by Cockcroft-111 
Gault formula. In the remaining patients, the Modification of Diet in Renal Disease (MDRD) 112 
equation was used to estimate GFR. Analysis of variance (ANOVA) was applied to compare 113 
daptomycin plasma concentrations within the groups. Correlation of daptomycin dose and 114 
daptomycin plasma concentration were analysed within these groups by simple linear 115 
regression analysis using SPSS Version 22 (IBM Corp, Armonk, NY).  116 
The independent association between daptomycin trough levels (Cmin), peak levels (Cmax) 117 
and the four renal function groups was investigated by multilevel linear regression analysis, 118 
taking into account repeated measurements in patients. The following covariates were included 119 
in the model to control for potential confounding: creatinine, dose interval, total administered 120 
dose (defined as total single dose administered on the sampling day), weight, gender, albumin 121 
plasma concentration and hospitalisation in a ICU. A separate analysis was additionally  122 
undertaken for dose normalized Cmax and Cmin (defined as Cmax or Cmin divided by total 123 
administered dose) at dose intervals of 24h or 48h. Total dose and dose interval were excluded 124 
as covariates for this analysis. Due to the skewed daptomycin trough and peak level 125 
distribution, regression analysis was performed on natural log (ln) transformed data. Residual 126 
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analysis was performed to check for the regression assumption. Analysis was performed with 127 
STATA Vers.12.1 (StataCorp LP, Texas). 128 
Daptomycin trough levels and their respective CPK values were recorded and possible drug-129 
induced CPK elevation was evaluated. CPK elevation was judged as possibly daptomycin 130 
related after exclusion of other causes (e.g. trauma or surgery) and the presence of a temporal 131 
relationship with daptomycin treatment. A toxicity threshold was defined as a daptomycin 132 
trough level of > 25mg/L based on the findings of Bhavnani et al., who reported an increased 133 
risk of CPK-elevation above a value of >24.3mg/L [15].  134 
 135 
Results  136 
Patient Characteristics 137 
Patient characteristics and indication for daptomycin treatment are represented in Table 1. A 138 
total of 86 patients were included. Four patients were excluded because of incorrect sampling 139 
time points. Eighty percent of the patients studied were hospitalized, at least transiently, in the 140 
ICU. Four percent of daptomycin concentrations were determined on an outpatient basis. 141 
Daptomycin plasma concentrations were most frequently determined in Enterococcus faecium 142 
infections (44%) and in coagulase negative Staphylococci (CoNS) infections (28%). The 143 
following pathogens were isolated in 36 blood cultures: 19 E.faecium, 6 methicillin-resistant 144 
Staphylococcus aureus (MRSA), 6 CoNS and 1 E.faecalis, vanocomycin resistant 145 
Enterococcus, methicillin-susceptible Staphylococcus aureus (MSSA), S.anginosus and group 146 
B Streptoccocus. Additional antibiotics effective against the infecting pathogen were used in 46 147 
patients (51%); 37 (41%) patients received daptomycin monotherapy. The remaining patients 148 
could not be evaluated either due to missing pathogen detection or unknown comedication.  149 
 150 
Daptomycin dosing  151 
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The median daptomycin dose administered was 6mg/kg (range 2.7-13.8mg/kg) and the median 152 
total dose was 500mg (150mg-1000mg). Data on daptomycin dosing interval in different renal 153 
function groups are shown in Table 3.  In 40 of 86 patients a high dose regimen (6mg/kg up to 154 
13.8mg/kg) was administered. 155 
In 10 patients, dose was adjusted based on daptomycin plasma concentration measurements. 156 
However, this was done in an unsystematic way solely dependent on the decision of the treating 157 
physician as no internal guidelines on target range were available. In 4 patients, the dose was 158 
increased based on Cmin <2mg/L, 5.4mg/L and 14.9mg/L. In 5 patients, the daily dose was 159 
decreased based on Cmin >50mg/L and 19.7mg/L and in one case based on a peak level of 160 
133mg/L. In one patient, the reason for dose change was unclear.  161 
 162 
Plasma concentrations 163 
A total of 332 daptomycin plasma concentrations were determined. Sixty-six percent (n=218) 164 
of all determinations were trough levels (Cmin) and thirty-four percent (n=114) were peak 165 
levels (Cmax). In patients with multiple sampling, a median of 2 Cmin samples and 1 Cmax 166 
sample were drawn per patient (range 0-14 and 0-15, respectively). Cmax was never 167 
determined in patients with CrCl ≤30mL/min. Cmin ranged 2- 68mg/L (median 16.7mg/L) and 168 
Cmax ranged 20-236mg/L (median 66.2mg/L). Time of first daptomycin measurement after the 169 
first dose or after a dose change ranged 1-80 days (median 4 days)  and 1-120 days (median 3 170 
days) for Cmin and Cmax, respectively. In 77% of patients determination of first daptomycin 171 
plasma concentration was performed after at least 3 days. When analyzed by renal function 172 
groups, only in patients undergoing CRRT significant correlations were observed between 173 
daptomycin dose (mg/kg) and Cmin (R
2
 0.23, p<0.05) or Cmax (R
2
 0.25, p<0.05). No 174 
significant correlation with dose administered was found in the other groups.  175 
The highest variability of daptomycin plasma concentrations was observed in patients with 176 
CrCl ≤30mL/min and CrCl >30mL/min without renal replacement therapy (CV% 81% and 177 
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72% in CrCl ≤30 and CrCl >30mL/min versus CV% 69% and 63% in IHD and CRRT) (Figure 178 
1a and 1b). Dose-normalized Cmin was more variable in patients with CrCl < 45mL/min than 179 
in patients with moderately impaired or normal renal function or in patients undergoing renal 180 
replacement therapy (Figure 2). In patients with CrCl ≤30mL/min and a dosing interval of 181 
q48h, Cmin values were all below 20mg/mL whereas in those patients with a dosing interval of 182 
q24h Cmin values higher than 20mg/mL were measured in 22% of the patients. Mean Cmin 183 
values in the 48h and the 24h group were 15.7 ±16.9mg/L and 39.4 ±21.0mg/L, respectively. 184 
This difference was statistically significant (student T-test p<0.05).  185 
Cmin levels were significantly lower in patients with CRRT compared to patients without renal 186 
replacement therapy independent of renal function (ANOVA p<0.005) (Figure 1a). Cmax was 187 
slightly lower in CRRT patients compared to other renal function groups but this difference 188 
was not statistically significant (p=0.49) (Figure 1b).  189 
When patients with severely impaired renal function (CrCl ≤30mL/min, IHD, CRRT) were 190 
compared to the CrCl >30mL/min group and controlled for creatinine level, dose interval, total 191 
dose, weight, gender, albumin concentration, and ICU hospitalisation in the multilevel 192 
regression analysis, patients with IHD were associated with lower Cmin (p=0.041), whereas 193 
association in the CRRT group was not statistically significant (p=0.227) (Table 2a). In the 194 
same analysis, a significant positive association of total daptomycin dose, albumin, creatinine, 195 
and a significant negative association of dose interval with Cmin were observed. The multilevel 196 
analysis determined total dose and ICU hospitalisation as factors significantly associated with 197 
Cmax (Table 2b, P<0.005). In a separate analysis of dose normalized plasma concentrations, 198 
Cmin/dose determined at 24h was negatively associated with dose interval, creatinine level and 199 
positively associated with ICU-hospitalisation. For Cmin/dose determined at 48h, a significant 200 
negative association of creatinine level, gender and albumin and a positive association with 201 
weight, were observed. For Cmax/dose determined at 24h, only patients undergoing CRRT 202 
were now associated with lower values compared with the CrCl>30mL/min group. No 203 
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significant association could be found for other covariates or clearance groups with Cmax/dose 204 
determined either at 24h or 48h. Overall, only 27% (adjusted R2 0.27, p<0.005), of Cmin 205 
variability and 8% (adjusted R2 0.08, P=0.08) of Cmax variability was explained by the 206 
covariates included into a multiple linear regression analysis. Residual analysis revealed no 207 
violation of the regression assumption.  208 
 209 
Safety 210 
 Cmin values > 25mg/L were found in 38% of patients with CrCl >30mL/min or CrCl 211 
≤30mL/min, in 17% of IHD patients and in 7% of patients undergoing CRRT. Overall, 20 cases 212 
of mild CPK elevation were found of which only 4 were considered possibly related to 213 
daptomycin treatment. In these patients the highest CPK values ranged 201-346 U/L and 214 
maximum Cmin values were 9.6mg/L, 23.5mg/L, 50.1mg/L and 14.3mg/L, respectively.  The 215 
last two patients were taking a statin concomitantly.  216 
 217 
Discussion 218 
In this retrospective survey we present daptomycin plasma concentrations derived from patients 219 
undergoing therapeutic drug monitoring whilst treated with daptomycin. Our data reflect the 220 
heterogeneity of a real-world hospital patient population in contrast to prospective 221 
pharmacokinetic studies published so far that report daptomycin plasma concentrations in 222 
defined patient populations under strict dosing regimens [7, 11, 14, 16, 17]. Accordingly, high 223 
variability in weight, comorbidities, treatment indications and dosing regimen was observed in 224 
our subjects and 60% had severely impaired renal function or were undergoing renal 225 
replacement therapy.  226 
We found that Cmin and Cmax values were associated with total dose administered and Cmin 227 
was additionally positively associated with creatinine clearance and albumin level and 228 
negatively associated with dose interval. Even when the analysis was undertaken separately for 229 
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the two dosing intervals, 24h and 48h, and dose normalized Cmin and Cmax, creatinine 230 
clearance remained associated with Cmin/dose. However, the covariates investigated accounted 231 
for only 27% of Cmin variability and 8% of Cmax variability. Thus, more than 70% of the 232 
Cmin variability and more than 90% of the Cmax variability remains unexplained in our model.  233 
Renal function has been identified as the main factor associated with daptomycin clearance in 234 
population PK studies that investigated patients with different grades of renal impairment or 235 
severe Gram positive infection[14, 18]. Additional factors influencing daptomycin PK were a 236 
considerably larger volume of distribution compared to healthy volunteers in patients with 237 
acute bacterial infections[7, 13, 14] and in patients with severely impaired renal function[18]. 238 
In a subset of patients with MRSA bacteraemia, highly increased daptomycin clearance was 239 
observed with significantly lower daptomycin exposure despite a comparable dose 240 
administered in all patients[7]. However, a significant proportion of daptomycin clearance 241 
variability remained unexplained[14, 18]. In view of these findings, TDM may me considered 242 
an important tool for individualized daptomycin dosing[7].  243 
Over one third of the subjects in our study were treated with a high dose regimen >6mg/kg. 244 
High dose daptomycin regimens of >6mg/kg have been recommended in complicated 245 
infections such as endocarditis, osteomyelitis and sepsis [6], whereas the maximum licensed  246 
dose is 6mg/kg for the treatment of S.aureus bacteraemia and right sided endocarditis.  The 247 
variability of individual dosing in our patients within the high dose regimen might reflect the 248 
fact that 80% of indications were off label treatments such as enterococcal and coagulase 249 
negative Staphyloccoci infections, left-sided endocarditis, foreign body infection or 250 
osteomyelitis for which exact dosing recommendations have not been established due to the 251 
lack of prospective controlled studies. This might lead to a further prescribing variability 252 
among physicians.  253 
Dosing intervals were not necessarily chosen according to product labelling, which 254 
recommends a prolongation of dosing interval to 48hours in patients with CrCl <30mL/min[3]. 255 
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In particular, in severely impaired renal function (CrCl <30mL/min without renal replacement 256 
therapy), we noticed the highest heterogeneity of dosing interval (Table 3). In nearly half of 257 
these patients, the dosing interval was not adjusted to 48hours. This generated very high Cmin 258 
values far above 20mg/L, in contrast to the adjusted interval with Cmin below 20mg/L after 259 
48hours. While correct dose use might reduce the risk for CPK-elevation, the 48h dose interval  260 
is still associated with significantly lower daptomycin exposure over 24h to 48h.   261 
The impact of low daptomycin exposure during the second day in a 48h dose interval regimen 262 
upon efficacy and risk of development of resistance is still unclear. Few data exist on efficacy 263 
and safety of daily daptomycin administration in severe renal impairment. In a case series, 264 
daptomycin was administered daily at doses of 6-8mg/kg in three patients with severe renal 265 
impairment (GFR 10-30mL/min) over several weeks with an improved efficacy and no CPK 266 
elevation[19]. However, daptomycin plasma concentrations were not monitored. The authors 267 
recommend high dose regimen administered daily as initial therapy for patients with very 268 
severe infections and a GFR of 10-30mL/min.  269 
A higher risk for CPK-elevation was associated with daptomycin trough concentrations of 270 
>24.3mg/L in a study by Bhavnani et al. [15] who analysed  daptomycin plasma concentrations 271 
derived from a pivotal clinical study investigating daptomycin in the treatment of bacteraemia 272 
and endocarditis caused by S.aureus[20]. In our patients, 25% of all Cmin values were above 273 
25mg/L. Concentrations as high as 68mg/L were tolerated without CPK elevation. This 274 
supports the fact that higher doses might be administered safely if needed for an efficient 275 
treatment. 276 
Significantly lower daptomycin Cmin and Cmax concentrations were observed in critically ill 277 
patients undergoing CRRT, despite a high percentage of patients receiving daptomycin q24h. 278 
Daptomycin pharmacokinetics in CRRT have recently been investigated by several groups[11, 279 
21-24] and a dosing interval q24h versus q48h has been discussed. The risk of under dosing on 280 
the second day after daptomycin administration in a q48h dosing regimen was also outweighed 281 
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against the risk of CPK elevation in q24h dosing. Our observational data here confirm our 282 
previously published prospective PK data in CRRT patients receiving 6mg/kg q24h [11] to 283 
ensure adequate daily drug exposure. As dose correlated significantly with daptomycin Cmin 284 
and Cmax values in CRRT patients, a high dose regimen q24h is probably necessary to ensure 285 
adequate daptomycin concentrations in critically ill patients who mostly suffer from severe 286 
infections. A study 8mg/kg q24h in CRRT is ongoing at our department.  287 
 288 
Limitations of this study are due to the retrospective design. In some patients data collection 289 
was incomplete and the exact sampling time point after daptomycin administration could not be 290 
verified. Therefore, differences in duration of daptomycin infusion or incorrect sampling time 291 
could be an additional factor for Cmax and Cmin variability. We did not assess treatment 292 
outcome because less than half of our patients received daptomycin as monotherapy and the 293 
number of microbiologically evaluable patients was small. Additionally, our patient population 294 
was very heterogeneous concerning comorbidities and renal function and they also differed 295 
with regard to dose, duration of therapy and surgical interventions.  296 
As we included only patients with daptomycin TDM performed, the population studied 297 
probably represents only a subset of the overall population treated with daptomycin at our 298 
institution. 50% of Cubicin® was in fact delivered to departments other than ICUs during the 299 
period of data collection, whereas 80% of our study patients were hospitalized in the ICU.   300 
 301 
Conclusion 302 
Our data demonstrate that, in an unselected patient population, daptomycin exposure is highly 303 
variable and is only partially explained by dose administered and underlying renal function. 304 
The factors accounting for most of the variability remains unclear and therefore daptomycin 305 
plasma concentrations are often unpredictable 306 
307 
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 373 
Figure legends 374 
Figure 1a and 1b  Daptomycin Cmin and Cmax values in different renal function groups 375 
Legend  376 
CrCl creatinine clearance, IHD intermittend hemodialysis, CRRT continuous renal 377 
replacement therapy, Cmin trough concentrations, Cmax peak concentrations.  378 
 379 
 380 
Figure 2  Dose normalized Cmin values in different renal function groups 381 
Legend 382 
Cmin trough concentrations, CrCl creatinine clearance, CRRT continuous renal 383 
replacement therapy, IHD intermittent hemodialysis. Filled circles represent q24h, triangles 384 
q48h and quads a q12h dosing interval. 385 
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